Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review-Reference-Cited by-同舟云学术

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

Published:2018-11 Issue:6 Volume:28 Page:764-774
ISSN:1952-4013
Container-title:European Journal of Dermatology
language:en
Short-container-title:Eur J Dermatol

Author:

Stewart Jacob R.,Desai Neil,Rizvi Syed,Zhu Hong,Goff Heather W.

Publisher

John Libbey Eurotext

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1684/ejd.2018.3444.pdf

Reference36 articles.

1. Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014; 70: 205.e1–16, quiz 21–2.

2. Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. ASH Educ Program Book 2015; 2015: 529–44.

3. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144: 818–31.

4. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

5. Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015; 8: 2–10.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023;European Journal of Cancer;2023-12

2. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome;Journal of Investigative Dermatology;2021-03

3. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update;Expert Opinion on Investigational Drugs;2019-08-18